Cacciamani Andrea

Dr. Andrea Cacciamani

Pubblications: PubMed

Operative Unit: Surgical retina Operating Unit

Sub-specialties: Cataract, Age-related Macular Degeneration (AMD), Retinal Vein Occlusion, Macular pathology of surgical interest, Diabetic retinopathy

Clinical activity: Major scientific and clinical interests are surgical and medical treatment of vitreo-retinal diseases, diagnostic techniques, laser and intravitreal treatments in ophthalmology. Major surgical activities includes cataract and vitreoretinal surgery and intravitreal injections


Education

1997 Degree in Medicine and Surgery (110/110 cum laude), University “La Sapienza”, Rome, Italy
2002 Residency in Ophthalmology (70/70 cum laude), University “Tor Vergata”, Rome, Italy

Roles

  • Since November 2017: Head of U.O.S. "Outpatient specialist area" of the IRCCS Department of Ophthalmology G.B. Bietti Foundation at the British Presidium of the S Giovanni Addolorata Hospital Complex in Rome.
  • Since 2015 to 2017: Assignment for teaching "Ophthalmology teaching" at the Faculty of Medicine of the Catholic University "Nostra Signora del Buon Consiglio" in the Degree Course in Nursing Sciences, headquarters of Elbasan (Albania).
  • Since December 2015 to today, Consultant of the IRCCS Department of Ophthalmology G.B Bietti Foundation at the British Presidium of the S Giovanni Addolorata Hospital Complex in Rome.
  • Since June 2008 to December 2015 Consultant of the S Giovanni Addolorata Hospital Complex - British Presidium of Rome at the Center for Maculopathies.
  • Since 2004 to May 2008 Consultant of the Department of Ophthalmology of the G.B Bietti Foundation at the San Pietro Fatebenefratelli Hospital in Rome.
  • In 2005-2006 he worked as Health and Medical Director in charge of the Institute for the blind and partially sighted of the “Sant'Alessio e Margherita di Savoia” Regional Center.
    Since 2002 Researcher of the IRCCS G.B. Bietti Foundation.
  • Since 2008 he has participated in 4 humanitarian missions as a volunteer physician in aid projects for emerging countries, designing and building small, decentralized surgical centers in the area and blindness prevention programs:
    • Mali city of Gao, organizer Fatebenefratelli-AFMAL in collaboration with the Italian Air Force.
    • Indonesia Island Lombok city of Kuta (two missions), organizer UNASOLAVITA-ONLUS.
    • Angola city of Huambo, organizer UNASOLAVITA-ONLUS in collaboration with the Trappist Sisters of the local Cistercian Monastery.
  • SOI (Società Oftalmologica Italiana) member
  • SIR (Società Italiana Retina) member

Sub investigator

  • A 12 months case series open study to assess the safetyand efficacy of intravitreal injection of Lucentis (Ranimizumab 0,5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondare to AMD (LUVI).
  • A randomization, doubl masked, active controlled, phase 3 study of efficacy, safety and tolerability of repeated doses of intravitreal VEGF-Trap-Eye in subjects with neovascular age-related macular degeneration (AMD)- VIEW2
  • A phase II prospective, randomised, multicentric diabetic macular edema dose ranging, comparation study evaluating the efficacy and safety of PF-04523655 versus laser therapy (DEGAS) 2008-present
  • A clinical safety and efficacy comparison of NEVANAC 0,1% to vehicle after cataract surgey in diabetic retinopathy patients (MIZAR)
  • RETAIN Study. A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs 0.5 mg ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus. Co-investigator.
  • COMO Study. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of Ozurdex® versus Lucentis® in patients with branch retinal vein occlusion. Co-investigator.
  • VIVID DME Study. A randomised, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macula edema. Treating investigator.
  • A multicenter, open-label, randomized study comparing the efficacy and safety of 700 μg dexamethasone posterior segment drug delivery system (DEX PS DDS) to Ranibizumab in patients with diabetic macular edema. Treating investigator.

Study coordinator

  • Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures. European Vision Clinical Research (ECR-RET-2010-02).
  • A randomized, double masked, sham controlled phase 3 study of the efficacy, safety, and tollerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO).
  • Open-label, multi-center, expanded access program with ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exists CRFB002DIT01-(PRIDE).

Reviewer of:

  • Cutaneous and Ocular Toxicology
  • Advances in Therapy

17 publications (pubmed) in peer reviewed scientific journals